Sierra Ocean LLC Makes New $44,000 Investment in Sanofi (NASDAQ:SNY)

Sierra Ocean LLC bought a new position in shares of Sanofi (NASDAQ:SNY) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 916 shares of the company’s stock, valued at approximately $44,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. lifted its holdings in Sanofi by 31.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company’s stock worth $8,040,000 after acquiring an additional 33,105 shares in the last quarter. Arkadios Wealth Advisors lifted its holdings in shares of Sanofi by 19.0% in the fourth quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company’s stock valued at $227,000 after purchasing an additional 751 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Sanofi by 7.1% in the third quarter. Geode Capital Management LLC now owns 254,738 shares of the company’s stock valued at $14,681,000 after purchasing an additional 16,780 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Sanofi by 20.9% in the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after purchasing an additional 399,301 shares in the last quarter. Finally, GFS Advisors LLC lifted its holdings in shares of Sanofi by 1,017.9% in the third quarter. GFS Advisors LLC now owns 12,800 shares of the company’s stock valued at $738,000 after purchasing an additional 11,655 shares in the last quarter. 14.04% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently commented on SNY shares. StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Finally, Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Sanofi presently has an average rating of “Buy” and an average target price of $60.00.

Sanofi Stock Performance

SNY opened at $54.50 on Tuesday. Sanofi has a 52-week low of $45.22 and a 52-week high of $58.97. The firm has a market capitalization of $138.31 billion, a PE ratio of 21.89, a PEG ratio of 0.99 and a beta of 0.57. The company has a debt-to-equity ratio of 0.15, a quick ratio of 0.74 and a current ratio of 1.46. The business’s 50-day simple moving average is $50.42 and its 200 day simple moving average is $52.47.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.58% and a net margin of 12.77%. As a group, sell-side analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.